TBPH

8.58

1.66% 0.14

Handel nachbörslich: 8.57 -0.010 -0.12%

Theravance Biopharma Inc (TBPH)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$8.44

Offen:

$8.53

24-Stunden-Volumen:

157.11K

Relative Volume:

0.90

Marktkapitalisierung:

$417.27M

Einnahmen:

$62.02M

Nettoeinkommen (Verlust:

$-45.65M

KGV:

-9.3261

EPS:

-0.92

Netto-Cashflow:

$-9.60M

1W Leistung:

-2.28%

1M Leistung:

-13.86%

6M Leistung:

-13.25%

1J Leistung:

-12.09%

1-Tages-Spanne:

$8.41

$8.59

1-Wochen-Bereich:

$8.35

$8.86

52-Wochen-Spanne:

$7.44

$10.44

Theravance Biopharma Inc Stock (TBPH) Company Profile

Firmenname

Theravance Biopharma Inc

Sektor

Healthcare (1174)

Branche

Biotechnology (684)

Telefon

650-808-6000

Adresse

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

TBPH's Discussions on Twitter

Vergleichen Sie TBPH mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TBPH Theravance Biopharma Inc	8.58	417.27M	62.02M	-45.65M	-9.60M	-0.92
VRTX Vertex Pharmaceuticals Inc	422.00	108.68B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	681.58	74.90B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	640.52	38.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	246.27	31.76B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	111.93	26.83B	3.30B	-501.07M	1.03B	-2.1146

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-06	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-04-12	Eingeleitet	BTIG Research	Buy
2024-01-08	Herabstufung	Evercore ISI	Outperform → In-line
2022-05-23	Eingeleitet	SVB Leerink	Outperform
2021-11-05	Hochstufung	JP Morgan	Underweight → Neutral
2021-09-15	Herabstufung	JP Morgan	Overweight → Underweight
2021-08-25	Herabstufung	Morgan Stanley	Overweight → Underweight
2021-08-24	Herabstufung	Cowen	Outperform → Market Perform
2020-10-14	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-07-07	Eingeleitet	JP Morgan	Overweight
2020-06-15	Eingeleitet	Morgan Stanley	Equal-Weight
2020-05-13	Eingeleitet	Cowen	Outperform
2020-01-08	Bestätigt	H.C. Wainwright	Buy
2019-11-06	Hochstufung	Robert W. Baird	Underperform → Neutral
2019-10-29	Eingeleitet	H.C. Wainwright	Buy
2018-03-29	Fortgesetzt	Piper Jaffray	Overweight
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-06-16	Eingeleitet	Cantor Fitzgerald	Overweight
2017-05-11	Bestätigt	Needham	Buy
2016-12-21	Eingeleitet	Needham	Buy
2016-11-03	Eingeleitet	Piper Jaffray	Overweight
2016-10-12	Herabstufung	Robert W. Baird	Neutral → Underperform
2016-08-03	Herabstufung	BofA/Merrill	Neutral → Underperform
2016-06-20	Eingeleitet	Guggenheim	Buy
2016-06-20	Bestätigt	Leerink Partners	Outperform
2016-05-12	Eingeleitet	Leerink Partners	Outperform
2016-05-05	Herabstufung	BofA/Merrill	Buy → Neutral
2015-02-03	Hochstufung	Robert W. Baird	Underperform → Neutral

Alle ansehen

Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten

Jan 18, 2025

Barclays PLC Increases Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Jan 18, 2025

Barclays PLC Has $529,000 Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat

Jan 18, 2025

How To Trade (TBPH) - Stock Traders Daily

Jan 18, 2025

Jan 17, 2025

Zacks Research Issues Optimistic Estimate for TBPH Earnings - Defense World

Jan 17, 2025

Jan 08, 2025

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Research Report 2024-2030 Featuring Allergan, Basilea Pharmaceutica, Merck, Pfizer, The Medicines Co, Theravance Biopharma - GlobeNewswire

Jan 08, 2025

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - GlobeNewswire

Jan 08, 2025

Jan 07, 2025

(TBPH) On The My Stocks Page - Stock Traders Daily

Jan 07, 2025

Analysts Are Optimistic We'll See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH) - Yahoo Finance

Jan 07, 2025

Jan 03, 2025

Franklin Resources Inc. Trims Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Jan 03, 2025

Barclays PLC Has $529,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Jan 03, 2025

Dec 30, 2024

Jane Street Group LLC Raises Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Dec 30, 2024

Dec 27, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by State Street Corp - MarketBeat

Dec 27, 2024

State Street Corp Decreases Stock Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Dec 27, 2024

Dec 19, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 21,372 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Dec 19, 2024

Wellington Management Group LLP Sells 159,258 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat

Dec 19, 2024

Dec 17, 2024

When (TBPH) Moves Investors should Listen - Stock Traders Daily

Dec 17, 2024

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference - PR Newswire

Dec 17, 2024

Dec 13, 2024

Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue? - MSN

Dec 13, 2024

Dec 11, 2024

The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable - Yahoo Finance

Dec 11, 2024

Dec 10, 2024

Diabetic Gastroparesis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Theravance Biopharma, Eli Lilly and Company, Processa Pharmaceuticals, PTC Therapeutics - The Globe and Mail

Dec 10, 2024

Dec 09, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat

Dec 09, 2024

Dec 07, 2024

What is Zacks Research's Estimate for TBPH FY2024 Earnings? - MarketBeat

Dec 07, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Acquired by BNP Paribas Financial Markets - MarketBeat

Dec 07, 2024

Dec 06, 2024

(TBPH) Trading Advice - Stock Traders Daily

Dec 06, 2024

Dec 04, 2024

Theravance Biopharma (STU:0TB) Shares Outstanding (EOP) : 49.17 Mil (As of Sep. 2024) - GuruFocus.com

Dec 04, 2024

Nov 30, 2024

105,609 Shares in Theravance Biopharma, Inc. (NASDAQ:TBPH) Bought by Algert Global LLC - MarketBeat

Nov 30, 2024

Nov 26, 2024

Trading (TBPH) With Integrated Risk Controls - Stock Traders Daily

Nov 26, 2024

Nov 21, 2024

Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN

Nov 21, 2024

Nov 20, 2024

Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail

Nov 20, 2024

Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizentribune

Nov 20, 2024

Theravance Biopharma to Present at Evercore HealthCONx Conference | TBPH Stock News - StockTitan

Nov 20, 2024

Madison Avenue Partners, LP Expands Stake in Theravance Biopharm - GuruFocus.com

Nov 14, 2024

Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 14, 2024

Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat

Nov 14, 2024

Nov 13, 2024

Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares - Investing.com India

Nov 13, 2024

Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares By Investing.com - Investing.com Canada

Nov 13, 2024

Earnings call: Theravance Biopharma reports growth in Q3 2024 - Investing.com

Nov 13, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat

Nov 13, 2024